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1. DNA vaccines
The development of vaccines has been one of the most
significant advances of modern medicine and has led to
improved public health and life expectancy. It has been
reported that two to three million lives per year are saved
worldwide due to vaccination.[1] The process of immunisation
was first observed in China and the Middle East in the
12th century. By using the skin or pustule liquid of patients
with smallpox, disease resistance in
another patient was achieved.[2,3] How-
ever, the first vaccine was developed in
1798 by Edward Jenner who reported
that injecting humans with cowpox led
to the protection against smallpox.[4] Conventional vaccines
are predominantly composed of inactivated (killed) patho-
gens or pathogen subunits, for example toxins, polysaccha-
rides or proteins, and live-attenuated (weakened) viruses.[5]
Antigens from these pathogens are recognised by the immune
system as being foreign, which results in the induction of an
immune response, the production of antibodies, and the
establishment of immunological memory. Successful tradi-
tional vaccines have been developed against numerous
bacterial and viral pathogens and have been most effective
for disease control.[6]
Unlike conventional vaccines, DNA vaccines are bacterial
plasmids designed to carry a specific encoding gene, which is
responsible for expression of the desired antigen in the host
and leads to the induction of an immune response.[7, 8] Instead
of using proteins from pathogens to stimulate the immune
system, DNA vaccines deliver an instruction for the protein to
be produced in the body (Figure 1). Major benefits of DNA
vaccines, compared to conventional vaccines, are high specif-
icity and the possibility of introducing additional sequences to
the plasmid, for example, adjuvants, which can potentiate the
immunostimulatory effect of the expressed antigen.[9] In
addition, the expressed immunising antigen is exposed to
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Over the last 30 years, genetically engineered DNA has been tested as
novel vaccination strategy against various diseases, including human
immunodeficiency virus (HIV), hepatitis B, several parasites, and
cancers. However, the clinical breakthrough of the technique is
confined by the low transfection efficacy and immunogenicity of the
employed vaccines. Therefore, carrier materials were designed to
prevent the rapid degradation and systemic clearance of DNA in the
body. In this context, biopolymers are a particularly promising DNA
vaccine carrier platform due to their beneficial biochemical and
physical characteristics, including biocompatibility, stability, and low
toxicity. This article reviews the applications, fabrication, and modi-
fication of biopolymers as carrier medium for genetic vaccines.
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Figure 1. Difference between conventional and DNA vaccines. Conven-
tional vaccines (left): After processing of the antigenic agent (e.g.
inactivated pathogens, pathogen subunits, live-attenuated pathogens),
the antigen is presented to the immune system by antigen-presenting
cells (APCs). DNA vaccines (on the right): The administered plasmid
DNA (pDNA) is endocytosed, released in the cytosol and taken up by
the nucleus, followed by transcription and translation into an antigenic
protein. This agent is presented to other cells of the immune system.
For both pathways, the antigen presentation results in downstream
signalling cascades evoking an immunological response and leading
to the establishment of an immunological memory.
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the same species-specific post-translational modifications
(e.g. phosphorylation or glycosylation) as the natural viral
infection. There is no need for live vectors or complex
biochemical production strategies. The interest in DNA
vaccines was further boosted by promising animal studies,
and generally, cheaper production as well as facile transport
and storage.
So far, DNA vaccines have been approved for veterinary
use against West Nile Virus in horses,[10] canine melanoma,[11]
infectious haematopoietic necrosis in farm-raised Atlantic
salmon,[12] and as gene therapy for growth hormone-releasing
hormone in pigs.[13] The first human trial of DNA-based
vaccines was conducted in 1998 and targeted human immu-
nodeficiency virus type 1 (HIV).[14] Currently, there are many
ongoing human clinical trials that target various types of
cancer, autoimmune diseases, and infectious diseases, such as
human papilloma virus (HPV), HIV, hepatitis B and corona-
virus (Table 1).[5,15]
Results of these first clinical trials reported DNA vaccines
to be safe and well tolerated, but showed low immunogenicity,
which was attributed to insufficient protein expression
levels.[5, 11] This low efficacy can be overcome by optimisation
of the plasmid-encoded antigen to increase antigen expres-
sion per cell or by increasing the transfection rate through
polymer and lipid formulations, as well as enhancement of the
immune response by addition of molecular adjuvants.[9]
Notably, mRNA vaccines have recently emerged as
another nucleic acid vaccination strategy, as reviewed by
Pardi et al.[16] and Maruggi et al.[17] The field of mRNA
vaccines gained significant traction and public media atten-
tion when BioNTech/Pfizer and Moderna presented the
results of Phase 3 clinical trials for their respective mRNA-
based COVID-19 vaccine candidates in late 2020. On
December 2, 2020, the Medicines & Healthcare Products
Regulatory Agency (MHRA) granted the worldwide first
temporary authorisation for the BioNTech/Pfizer vaccine in
the UK, marking an important milestone in the fight against
the global coronavirus pandemic and thus making it the first
genetic vaccine approved for human use. Both BioNTech/
Pfizer and Moderna employ mRNA that encodes for different
subunits of the S protein of SARS-CoV-2. Major limitations
of the technology, e.g. low delivery efficacy and stability
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concerns in vivo, were overcome using sophisticated nano-
technology. The mRNA is encapsulated in lipid nanoparticle
formulations to protect it against rapid nuclease degradation
in vivo and deliver it efficiently to the cytoplasm.[18] In
contrast to DNA vaccines, mRNA vaccines do not require
entry to the nucleus and efficient transcription, thereby
excluding the risk of insertional mutagenesis. However, DNA
vaccines are known to be generally more stable than mRNA.
Herein, we will give an overview of biopolymer-based
formulations with emphasis on nanostructured biopolymers
as carriers for DNA vaccines and introduce modifications that
have been shown to enhance vaccine efficiency. Due to the
comparable mechanism of action of DNA vaccines and
mRNA vaccines, the design considerations presented in this
Review may also be useful for mRNA vaccine delivery
systems.
1.1. DNA Vaccines: Mode of Action
The administration of DNA vaccines leads to the trans-
fection of cells at the injection site. Upon internalisation and
translocation to the nucleus, resident cells, such as keratino-
cytes in the skin and myocytes in muscle tissue, express the
Table 1: Active clinical trials using DNA-based vaccines. Data collected from www.clinicaltrials.gov on 14 July 2020.





Viral infection vaccines INO-4800 Coronavirus I NCT04336410
GX-19—plasmid S-protein antigen Coronavirus I/II NCT04445389
AG0301 Coronavirus I/II NCT04463472
Gn and Gc Hantaan virus plasmid Hantaan I NCT02776761
Interleukin-12 (IL-12) DNA HIV I/II NCT03606213
VGX-3100 HPV II NCT03603808
Cancer vaccines pTVG-HP vaccine + Pembrolizumab Prostate and metastatic
cancer
II NCT04090528
pTVG-HP vaccine + nivolumab Prostate cancer II NCT03600350
Neoantigen DNA + nivolumab/pilimumab Metastatic Prostate Cancer I NCT03532217
Neoantigen DNA + durvalumab Breast cancer I NCT03199040
GNOS-PV02 + IL12 + Pembrolizumab Hepatocellular carcinoma I/II NCT04251117
VEGFR-2 expressing pDNA + Avelumab Recurrent Glioblastoma I/II NCT03750071
Mammagloblin-A Breast cancer I NCT02204098
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine Cervical intraepithelial
neoplasia
I NCT00788164
IFx-Hu2.0 plasmid encoding S. pyogenes bacterial anti-
gen Emm55
Cutaneous Melanoma I NCT03655756
MEDI0457 + Durvalumab Oropharynx Cancer II NCT04001413
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope pDNA
Vaccine
Breast cancer I NCT02157051
Cancer + viral infection
vaccines
HPV E6/E7 DNA vaccine GX-188E + Pembrolizumab Cervical cancer,
HPV
I/II NCT03444376
IL-12/HPV DNA plasmid + Durvalumab Metastatic melanoma,
HPV
II NCT03439085
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine + Imi-
quimod
Cervical cancer, HPV I NCT00788164
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vaccine-encoded antigen and eventually excrete it through
apoptosis or exosomes.[19] APCs, such as dendritic cells (DCs),
circulate searching for pathogenic structures, detect and
internalise the exogenous antigen and introduce it to their
endolysosomal degradation pathway. The DCs then progress
to the lymph nodes, where they present peptide fragments
stemming from the antigen to CD4 + T cells. The activation of
CD4 + T cells is achieved through the association of the
major histocompatibility class II (MHCII) complex on APCs
and the T-cell receptor on CD4 + cells and supported by
further interaction through co-stimulatory ligand–receptor
binding. MHC complexes are a set of genes coding for MHC
cell surface glycoproteins, which present pathogen fragments
to T cells and thus help the immune system to recognise
a threat.[20] CD4 + T cells play a major role in orchestrating
the immune response by contributing to B cell priming and
the activation of cytotoxic CD8 + T cells.[21, 22] Furthermore,
exogenous antigens can be cross-presented from transfected
apoptotic somatic cells to immature CD8 + T cells through
the MHCI pathway, which results in the activation of
cytotoxic T lymphocytes (CTL), triggering a strong cellular
immune response.[23]
In addition to this indirect route, DCs can also be directly
transfected by DNA vaccines. The direct route involves the
endocytosis and expression of the DNA vaccine in DCs, which
results in the parallel activation of CD8 + cytotoxic T cells
and distinct CD4 + T helper cells through the binding with
MHCI and MHCII, respectively, as well as with the specific
co-stimulating receptors.[24]
Upon activation, immature CD8 + and CD4 + T cells
begin to proliferate due to the autocrine production of IL-2,
a T cell growth and differentiation factor (Figure 2). CD8 +
T cells clonally expand upon the interaction with IL-2 to
increase the effective amount of cytotoxic, antigen-specific
T cells. CD4 + T cells, however, start to differentiate upon
binding to IL-2 and become T helper cells (Th0). These helper
cells produce IL-2, IL-4, and interferon gamma (IFN-g) and
can further proliferate into Th1 and Th2 effector T cells. Th1
cells are responsible for activating the cellular immune system
by further supporting the proliferation of cytotoxic CD8 +
T cells.[25] In contrast, Th2 cells stimulate the humoral
immune response by inducing B cell-mediated antigen pro-
duction. In this way, DNA vaccines can trigger both a humoral
and cellular immune response, which is a significant advant-
age over commonly used vaccines.[26] While the humoral
immune response targets extracellular pathogens, cellular
immunity is responsible for annihilating intracellular patho-
gens, such as cells infected with viruses or bacteria.
The proliferation into Th1 or Th2 cells can be modulated
by changing the mode of administration. While intramuscular
administration was shown to mostly induce Th1-type immune
response, intradermal treatment results in a strong humoral,
Figure 2. Mode of action of DNA vaccines. Extracellular antigens, stemming from keratinocytes or myocytes, are presented to naive CD4+ T cells
through the MHCII pathway (I), which leads to clonal expansion and differentiation to Th0. While the interaction of Th0 with IL-12 results in the
formation of Th1, the binding to IL-4 promotes the stimulation of B cells, which eventually form antigen-specific antibodies and memory B cells.
Extracellular antigens can also be introduced to the MHCI pathway through cross-presentation (II). In addition, APCs can be directly transfected
with pDNA. After cellular uptake (III), APCs express pDNA (IV) and present the resulting antigen through the MHCI pathway (V) to naive CD8+
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or Th2-mediated, immune response.[21] Furthermore, this
multifaceted mechanism leads the formation of long-living
memory B and T cells to form an integral part of the adaptive
immune system, which allows for a faster and stronger
immune response after repeated infection with a previously
encountered antigen.[27]
1.2. Design of DNA Sequences
pDNA sequences used in vaccine design are typically
comprised of an expression (or transcription) unit and
a production unit (Figure 3). The transcription unit consists
of a viral-hybrid or eukaryotic promoter region (I), an
intron (II), a sequence that encodes the antigen of interes-
t (III), and a polyadenylic acid (polyA) signal (IV).
The promoter sequence (Figure 3, I) provides a strong
binding site for RNA polymerase and thus controls the
transcription of the plasmid into mRNA, which is eventually
translated into the desired antigen of interest. The most
commonly used promoter stems from the human cytomega-
lovirus (CMV), as it drives high antigen expression levels in
various cell lines.[28] However, viral promoters are quickly
deactivated through gene silencing and often show only
transient gene expression. Therefore, viral/mammalian
hybrid-promoters, such as a combination of CMV and the
human elongation factor 1a promoter, can be employed to
delay the deactivation effects caused by gene silencing in vitro
and in vivo.[29]
Typically, an intron sequence (II) is introduced between
the promoter (I) and the antigen of interest (III) region on
the plasmid. Introns are non-coding regions in a gene and
were found to increase the antigen expression efficacy
significantly.[30] The intron is followed by the antigen of
interest (III) region, which codes for the desired immuno-
genic protein. The final element of the transcription unit is
a polyA signal (IV), which stabilises the mRNA transcripts
and eases the export from the nucleus.[31, 32]
The production unit consists of an origin of replica-
tion (V) sequence and antibiotic resistance genes (VI). The
origin of replication is needed to amplify the plasmid in the
host cell, and typically consists of a bacterial region,
responsible for successful replication and selection in a bacte-
rial host, and an eukaryotic region, which allows for the
expression in mammalian cells.[33] The antibiotic resistance
genes facilitate the antibiotic-selected plasmid production in
bacterial cultures. However, legislators strongly discourage
the use of antibiotic resistance genes in in vivo trials to
prevent potential antibiotic resistance of the patient and the
integration into the human genome.[34]
1.3. Delivery of DNA Vaccines
To date, no DNA vaccine has been approved for use in
humans. The major challenge for DNA vaccines still resides in
insufficient gene expression and low immune system activa-
tion. In order to overcome this, research has been focusing on
DNA sequence design, vaccine formulation, and the mode of
delivery.[35]
In terms of delivery, conventional needle-based delivery
approaches can be classified into intradermal, subcutaneous,
intravenous, and intramuscular injection with varying depth
of skin penetration.[36] Intradermal delivery is considered to
be more effective than intramuscular or subcutaneous
injection due to the dense DC network present in the
dermis.[37] Intravenous application is performed with the
goal to deliver DNA plasmids to APCs in secondary lymphoid
organs, although with varying effectiveness.[36]
Alternatively, DNA vaccines can be delivered via mucosal
barriers by, for example, oral, nasal, or pulmonary uptake,
which induces local immunity at mucosal sites as well as
whole-body immunity.[38] Mucosal immunisation is regarded
to be effective against viruses, as host infection is primarily
induced by entering through mucosal surfaces.[38, 39] Moreover,
these methods are particularly user-friendly, as they do not
require needles, specialised equipment, or skilled opera-
tors.[39]
However, administration of naked DNA through these
routes lacks major features desirable for robust immunisation,
such as in vivo stability, specific targeting, high cellular
uptake, and immune system modulation. Hence, delivery via
the skin has been enhanced by use of electroporation,
microneedles, or needle-free delivery systems such as gene
guns or biojectors, all of which require specialised equip-
ment.[36, 37] Delivery efficacy can additionally be increased by
combining the pDNA with suitable carriers, which not only
improves the plasmid stability, but can also enhance gene
expression and immune response. Biopolymers have recently
emerged as suitable carrier materials and have significantly
increased the potential of DNA vaccine formulations.
Figure 3. Design of pDNA vaccine sequences. The plasmid can be
divided in a production and transcription section. The production unit
is responsible for successful replication in the host and consists of an
origin of replication and antibiotic resistance gene region. In contrast,
the transcription section consists of a promoter region, commonly
separated from the antigen of interest sequence by an intron. The
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2. Biopolymers as DNA Vaccine Carriers
Liposomes, polymers, virosomes, cell-penetrating pep-
tides (CPPs), and live bacteria have been successfully used as
DNA carriers (Figure 4).[35, 37,40] Amongst these, polymers
show high physicochemical versatility and low toxicity,
provide protection from enzymes that can interfere with the
structural integrity of the vaccine, and enable, cost-effective
production.[41] Furthermore, they are more rigid and stable
than liposomes and do not pose risks regarding anti-vector
immunity as in the case of virosomes and live bacteria.[37,42]
An additional advantage of polymers is the ability to design
various nanostructures with tuneable size and different
surface properties, which have been particularly useful for
the design of smart drug delivery systems. In fact, a number of
polymer nanoformulations have already been approved for
clinical use.[43, 44] Among polymers for DNA vaccine design,
biopolymers (Table 2) are preferred over synthetic polymers
due to their biocompatibility, favourable cellular interactions,
biodegradability, and often facile production, for example
with the help of bacteria or using enzymes.[45] Biopolymers are
polymers which are naturally formed by living organisms.[46]
In a broader sense, they can be defined as synthetic polymers
made from monomer units obtained from living organisms,[47]
such as crustaceans, seaweed, and corn.[48–50] The following
sections will give an overview of the most significant advances
that emerged from the development of biopolymer carriers
and their use in DNA vaccine formulation.
2.1. Design of Biopolymer Vaccine Carriers
Biopolymeric DNA vaccine systems contain at minimum
a core scaffold and the pDNA. The biopolymer core can be
modified with functional moieties or co-polymers to enhance
the vaccine delivery (Figure 5). The pDNA can either be
adsorbed on the surface of the nanoparticles (NPs)[101, 102] or
incorporated within the core.[48, 103–105] Further modification of
these basic designs can be made by addition of polymeric
shells,[51, 105] the deposition of NPs in a polymer matrix,[105–107]
and preparation of compounded NPs composed of two
different material domains within the particle.[108, 109] More-
over, metal-based NPs, such as gold[110] and iron oxide
NPs,[111,112] liposomes,[113–115] and a range of hydrogels have
been used in combination with biopolymers to introduce new
functionalities.[99, 116, 117]
When designing DNA vaccine carrier materials, different
biological barriers need to be taken into account. On an
extracellular level, these include the rapid clearance of
foreign genetic material from the bloodstream, deactivation
through serum proteins, and degradation of DNA through
DNases. Once the target cell is reached, carrier-bound DNA
needs to be internalised through the membrane via phago-,
pino-, or endocytosis. Finally, upon internalisation, the
vaccine is required to escape phago- or endosomal vesicles
and travel across the cytoplasm to reach the nucleus, where
DNA needs to dissociate from the carrier to enable the
expression of the encoded antigen.[118]
In short, the DNA carrier not only needs to ensure the
integrity of pDNA, but also needs to be equipped with
functional groups that enable stability in biological fluids,
prolonged circulation to reach target cells, overcoming of
extracellular and intracellular barriers, and safe delivery to
the nucleus. This might seem like a formidable challenge, but
significant advances have been made in the past decade that
took us closer to the rational design of successful DNA
carriers. The next sections will give an overview of the most
important strategies applied to increase the efficacy of DNA
vaccines using biopolymer carriers.
Figure 4. DNA vaccine carriers: liposomes, polymers, virosomes,
CPPs, and live bacteria.
Figure 5. Biopolymer-based DNA vaccine delivery designs. Nanostruc-
tured biopolymers, which can include additional elements such as
functional moieties or co-polymers. Commonly employed designs
include NPs with both surface-adsorbed and incorporated pDNA.
Nanocarriers can be further enclosed by polymer layers or incorporated
in compounded formulations or polymer matrices. Advanced systems
include NPs with metallic cores, the use of liposomes, or hydrogels.
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Table 2: Properties of biopolymer examples used for pDNA vaccine delivery.
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2.2. Strategies for Improved DNA Condensation
The association of DNA and the biopolymeric material is
crucial to assemble a successful delivery system, as the
effective binding results in pDNA protection, and ensures
efficient cell uptake. In case of an unstable pDNA immobi-
lisation, premature release of the plasmid can occur, which
results in lower transfection efficacies and hence a weaker
immune response.[119]
By far the most widely exploited strategy that aids pDNA
condensation is the use of positive charge. The electrostatic
interaction between the negatively charged phosphate group
in the DNA backbone and positive charges of the carrier
material provides a suitable non-covalent association strategy
for DNA condensation. This phenomenon can be observed in
nature, where electrostatic interaction has been adopted for
condensation of DNA, for example around the histone or
protamine proteins, which are rich in basic amino acid
residues.[120, 121] Numerous biopolymers, among them chito-
san,[101, 108, 109,122–126] ePLL,[84,127] poly-l-lysine (PLL),[67, 105,128–133]
protamine,[76, 79, 80, 134–137] polyarginine,[67, 90,91, 138] and polysper-
mine[89, 139–141] (Table 2), bear intrinsic positive charge, making
them excellent candidates as DNA condensation agents.
Positive charge can also be introduced to the carrier core
by addition of synthetic polymers such as polyethylenimine
(PEI),[64, 92, 147,93, 111, 127,142–146] polyurethane,[148] amino poly(gly-
cerol methacrylate),[149] or positively charged dendrons.[150,151]
Due to the high density of positive charges, high buffering
capacity, and availability, PEI is a widely explored synthetic
polyamine in DNA delivery and frequently termed as the
“gold-standard” in polymer-mediated gene delivery.[152] In
addition, covalent functionalisation of biopolymers with
positively charged amino acids, peptides, or small molecules
(Figure 6) can be used for charge tuning. For example,
arginine, histidine, and lysine were employed to functionalise
dextran,[153–155] chitosan,[51] alginate,[59] human serum albumin
(HSA),[78, 156] HA,[116] and chondroitin sulfate.[157] Other small
moieties used for biopolymer modification include quater-
nary amines,[56,73, 158–160] spermine,[63, 161,162] piperazine,[163] cyst-
amine,[69] and succinyl tetraethylene pentamine.[164]
Moreover, the polymer backbone itself can be chemically
modified to modulate its intrinsic charge. Chitosan, which is
positively charged only at acidic pH, can be trimethylated at
its primary amines resulting in a positive charge over
a broader pH range.[55, 165–168] In case of proteins such as
albumin, methyl esterification of carboxyl groups decreases
negative charge and renders the overall protein positively
charged and well-suited for DNA condensation.[169]
Alternatively, hydrophobic attraction can be employed to
attach pDNA onto the carrier. To achieve this, pDNA can be
hydrophobised with cetrimonium bromide[170] or dioleoyl-3-
trimethylammonium propane.[98, 171–173] The advantage of such
an approach is that the carrier material is not only limited to
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PLGA particles
[a] Generally recognised as safe (GRAS) is an FDA designation that a substance added to food is considered safe. [b] GI: gastrointestinal. [c] FDA:
Food and Drug Administration (USA).
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negatively charged or neutral polymers, since electrostatic
binding is no longer the driving force for DNA condensation
(Figure 7). This approach led to efficient immobilisation of
pDNA to 5b-cholanic acid-modified chitosan,[170] and 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-conjugated
HA,[171] as well as for the incorporation of DNA within the
hydrophobic core of PLGA particles.[98, 172, 173]
In addition to the use of positive charge and hydrophobic
interactions, hydrogen bonding can be exploited to condense
DNA.[174] For example, guanidinium moieties in arginine-
containing materials were shown to form hydrogen bonds
with phosphate groups in the backbone of DNA and were
successfully used for DNA condensation. Furthermore, these
groups interact with the cell surface, which significantly
improves the cellular uptake.[174, 175]
Another strategy to enable condensation is the use of
coordinating multivalent metals cations that can bind to
phosphate groups or nucleobases.[176, 177] Zinc ions have been
employed to aid the interaction between phosphate groups of
DNA and two different biopolymeric species, histidine-
conjugated PLL[178] and dipicolylamine-modified HA,[179] but
there is definite scope for use of other ions, particularly those
that might be helpful adjuvants, including nickel, beryllium,
cobalt, and palladium.[180] In addition to being an excellent
coordinating ion, incorporation of zinc ions via histidine has
been shown to increase endosomal release increasing the rate
of transfection.[178]
2.3. Improved Stability and Solubility of DNA Biopolymer
Systems
Stability and solubility of DNA vaccine formulations are
not only essential to ensure the efficacy and safety of the
vaccine post administration,[181] but also to enable long-term
storage without compromising the product quality.[182] Nota-
bly, stability considerations need to be taken into account
when deciding on the route of administration (e.g. oral,
parenteral) and the dosage form (e.g. dry powder, suspension)
of DNA vaccines.
One of the stability issues commonly encountered with
nanoformulations and the production of NP carriers is
aggregation, which is especially important for suspension
formulations.[183] NPs are characterised by high surface-area-
to-volume ratios, resulting in a high surface energy. Conse-
quently, these particles tend to form thermodynamically
favourable aggregates with lower overall surface energy,
particularly in biological media.[183, 184]
To prevent aggregation, a surface coating with hydrophilic
polymers, such as polyethylene glycol (PEG), can be intro-
duced to the nanoformulation. PEG has been shown to
prevent particle interaction and increase their circulation
time in blood, thus enhancing the probability of reaching the
targeted tissue. PEG surface modification has been demon-
strated for PLGA-,[98] PDA-,[185] gelatine-,[186, 187] polysper-
mine-,[141] and PLA-based[188] DNA carriers.
Shielding against aggregation of positively charged deliv-
ery systems can also be achieved using the negatively charged
biopolymer chondroitin sulfate.[67] Coating PLL,[67] dendri-
graft PLL,[129] poly-arginine,[67] and protamine[135] NPs with
chondroitin sulfate has shown to reduce agglutination with
erythrocytes and cytotoxicity associated with highly positively
charged delivery systems.[157] Furthermore, Hashimoto and
co-workers showed that functionalisation of chitosan with
hydrophilic lactose residues supressed self-aggregation as
well as aggregation of chitosan NPs with serum proteins.[189]
Proteins abundant in blood, such as HSA[78, 143,190] and
bovine serum albumin (BSA),[149] known for their role in the
transport of various biologically important molecules, ranging
from hormones to fatty acids, have also been employed as
nanocarriers for gene delivery. As they are naturally present
in the blood circulation, unfavourable interactions with other
serum proteins are minimised, ensuring low levels of aggre-
gation and favourable pharmacokinetic profiles.[190]
In terms of chemical stability, pDNA needs to be well-
protected from degrading DNase enzymes. One way to
achieve this is to pack the pDNA within the NP core to
block the enzyme access.[96, 191] However, it was shown that
enzyme degradation can also be minimised by adsorption of
pDNA on the surface of the carrier.[77,82] This is thought to be
due to the deformation of pDNA upon binding to nanosized
spheres[192] as well as to steric hindrance posed by the carrier
core.[193]
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Considering different routes of DNA vaccine delivery,
administrating genetic vaccines via the oral route presents an
appealing alternative to intradermal or intramuscular injec-
tion due to its non-invasive and convenient nature, and
because of low sterility concerns.[194] In addition, it was shown
that oral administration is particularly interesting for local
therapy of GI diseases, such as dental caries,[195] colorectal
cancer,[196] and inflammatory bowel disease, that is, CrohnQs
disease and ulcerative colitis.[197] However, oral delivery
systems are faced with especially challenging chemical
stability issues. Upon oral administration, the nanoformula-
tion encounters the highly acidic stomach environment, which
is crowded with gastric enzymes that can degrade the carrier
material, thus impeding DNA delivery. This can be overcome
by careful design of scaffold materials and DNA-interacting
species. For example, it has been shown that alginate nano-
spheres can efficiently protect DNA when passing the GI tract
and facilitate GI epithelial uptake through superior mucoad-
hesive and mucopenetrating properties.[198, 199] Furthermore,
tertiary systems comprised of alginate, chitosan, and pDNA
were more efficient for in vivo oral delivery than chitosan/
pDNA NPs alone.[200,201] This is probably due to the dissoci-
ation of alginate–chitosan crosslinks at pH 1.5, which results
in the formation of a protective layer of insoluble alginate on
the carrier surface.[201] Furthermore, the introduction of
polycaprolactone and poly(2-hydroxyethylmethacrylate) to
gelatine and chitosan NPs, respectively, proved to be a good
strategy to protect DNA cargo from the harsh conditions of
the GI tract.[202, 203]
The protein zein can be used as oral DNA vaccine carrier
as well. Its amphiphilic character, owing to its hydrophobic
amino acid content of over 50 % and high glutamine content,
facilitates aggregation into NPs with hydrophobic cores and
hydrophilic outer shells. In acidic environments, such as in the
stomach, zein nanocarriers are insoluble, extremely resistant
to the low pH, and have been shown to protect their? cargo
from enzymatic degradation.[48, 87] It has been demonstrated
that immunisation of mice with chitosan carriers modified
with an outer shell of zein leads to higher antibody titers
compared to mice vaccinated with particles lacking zein.[88]
Finally, it is desirable to develop DNA-carrier systems
stable during storage and transport without extensive cooling,
which can be energy demanding and not suitable for low
income countries. Designing carriers that enable storage and
transport at room temperature is a significant advantage over
existing strategies, and has been successfully demonstrated
for HA and chitosan-containing NPs, which remained stable
both in lyophilised and liquid form over 12 months at ambient
conditions.[204]
Closely related to the stability and key to successful DNA
vaccine formulations is the solubility of the carrier material.
Many biopolymers used for the design of DNA vaccines are
intrinsically soluble in aqueous media. However, some
commonly used biopolymers, such as chitosan, show only
limited solubility at physiological pH. This can be overcome
by increasing the hydrophilicity of the polymer backbone
through chemical modification, such as the deacetylation of
residual acetylated amines,[205,206] introduction of carboxy-
methyl moieties to the C6 hydroxy group,[56,68, 207, 208] trime-
thylation,[55,165–167, 207, 208] or addition of larger hydrophilic
groups such as N-[(2-hydroxy-3-trimethylammonium)pro-
pyl]chloride[56, 159] and polymeric methacrylates.[209]
2.4. Improved Cell Uptake
In order to increase the immune response and therapeutic
activity of DNA vaccines, efficient delivery and release of the
genetic cargo within the targeted cell is crucial. Cellular
uptake is one of the most significant steps to ensure the
biological activity of vaccines, and it depends on the
interaction between the cell membrane and the carriers,
which can result in several endocytotic pathways as shown in
Figure 8.[210] The internalisation depends on the cell type as
cells bear different types and numbers of membrane proteins
and lipids, as well as on the physiochemical properties of the
carrier.[211] We will not go into details on cellular uptake and
release of nucleic acids, since these have been reviewed by
Degros et al. ,[212] Medina-Kauwe et al.,[213] and Zhou et al.[214]
In the following sections, we will discuss properties of
biopolymers that have been reported to promote different
routes of DNA vaccine uptake.
2.4.1. Non-Specific Cell Uptake
Non-specific, adsorptive endocytosis is promoted by
cationic polymers to a higher degree than by negatively
charged or neutral molecules.[152] Endocytosis is enabled by
adsorption of the positively charged DNA–polymer systems
with negatively charged proteoglycans on the outer cell
membrane surface.[174, 215]
In addition to the strategies for the introduction of
positive charge reviewed in Section 2.2, non-specific cellular
uptake can be facilitated through the use of CPPs (Figure 9,
left).[78, 90] CPPs are short, positively charged peptides that can
translocate across the cell membrane without impairing the
cellular integrity and were first discovered in viral proteins.
Although the mechanism of action is complex and beyond the
scope of this Review, their positive charge plays an important
role to facilitate the adsorption onto the negatively charged
cell membrane leading to the uptake through several
endocytic pathways.[210, 216] A commonly used CPP is HIV-
1 transactivator of transduction sequence (Tat), which was
found to enhance gene transfection efficiency. The introduc-
tion of both Tat and arginine-glycine-aspartate (RGD)
peptide was shown to significantly increase the efficiency of
HSA nanovectors.[78] It was also demonstrated that the degree
of cross-linking to the polymer backbone had a pronounced
influence on the properties of the carrier. Besides positively
charged polymers and CPPs, calcium ions (Ca2+) can be used
to aid cell internalisation as well as endosomal escape. Ca2+
ions mediate several cell processes, including induction of
endocytosis. It was demonstrated that the favourable gradient
for transport of these ions into the cell (Ca2+ concentration is
104 times higher in the extracellular space compared to the
cytoplasm) plays an important role in gene delivery.[217] Ca2+-
modified alginate-sulfate NPs were investigated as DNA
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delivery systems and mechanistic studies indicated the
possibility of clathrin-mediated endocytosis.[218]
However, it was reported that large amounts of positively
charged polymers, especially if bearing high charge density,
can cause cytotoxicity[219] and promote nonspecific interaction
with negatively charged serum proteins and subsequent
clearance by the reticuloendothelial system.[220] That indicates
the importance to control the amount of positive charge and
charge density.
One approach to reduce positive charge without reducing
non-specific cellular uptake includes introduction of hydro-
phobic moieties such as phenylalanine[102] or oleoyl groups[68]
to the positively charged polymer backbone. Although this
was shown to decrease the toxicity and enhance cellular
uptake through hydrophobic interactions with the cell
membrane,[221] careful introduction of such modifications is
needed in order to avoid significant decrease in solubility and
the stability of the system.
2.4.2. Target-Specific Cell Uptake
Targeting ligands can enhance accumulation of the carrier
system in a specific tissue or cell type, minimise non-specific
uptake, and facilitate internalisation. Small molecules, such as
folate,[141, 148,163, 222, 223] alendronate,[224] lactose,[189] man-
nose,[113, 225–227] and TLR7 agonist,[208] as well as pep-
tides,[207,228, 229] oligonucleotides,[187] and poly-
mers[68, 129, 142, 172,173, 222] have been introduced to biopolymer-
based nanovectors in order to improve targeting of specific
receptors (Figure 9, right). In addition to the choice of ligand,
Figure 9. Design strategies to enhance cell uptake of DNA vaccine carriers. Cationic polymers, CPPs, and hydrophobic substituents can promote
non-specific cellular uptake. Targeting lectin-binding receptors (mannose receptor or DEC-205) and toll-like receptors (TLR2 or TLR7) can facilitate
accumulation in APCs. Targeting tumour-specific receptors (folate, CD44) can increase uptake by cancer cells.
Figure 8. Internalisation of nanocarriers. Internalisation can occur through a number of endocytic pathways: pinocytosis (clathrin-mediated
endocytosis, caveolae-mediated endocytosis, clathrin/caveolin-independent endocytosis), phagocytosis, and macropinocytosis. Once internalised,
the cargo is entrapped in endosomes and eventually ends up in the lysosome. The pDNA should evade endolysosomal degradation and enter the
cytoplasm by endosomal escape to enable pDNA translocation into the nucleus for transcription.
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control over surface density is essential to achieve high
targeting efficiency and internalisation.
Specific delivery and enhanced uptake of DNA vaccines
into APCs has been associated with effective immunisation.
Lectin-binding receptors, such as mannose receptors CD206
and DEC-205, are abundantly expressed on the surface of
APCs, including macrophages and DCs,[225–227, 230] and intro-
duction of mannose enables preferential uptake of
APCs.[113, 225–227]
The DEC-205 receptor is particularly interesting, as it
initiates MHCI and MHCII pathways by antigen endocytosis,
leading to the stimulation of both CD4 + and CD8 +
T cells.[231] To enable DEC-205 targeting, Suresh et al. fused
anti-DEC-205 antibody to pDNA-loaded chitosan and
designed a DNA vaccine against severe acute respiratory
syndrome coronavirus (SARS-CoV) nucleocapsid protein.[228]
This carrier has demonstrated that targeted delivery to nasal
DCs is a potent strategy to achieve enhanced immunogenicity
of a low-dose DNA vaccine.
In addition to lectin-binding receptors, TLRs have been
explored for macrophage targeting. Modification of chitosan
NPs with TLR agonists, TLR-7[208] and TLR-2,[207] has
significantly increased IL-8 levels in THP-1 macrophages
compared to bare chitosan NPs.
As mentioned in the introduction, DNA vaccines repre-
sent a promising strategy to induce a specific long-term
immune response. This is particularly interesting for the
induction of an immunological memory and systemic immune
response in cancer treatment.[232] Besides targeting receptors
on APCs, different cancer types can be treated by induction of
specific CTLs. Namely, folate and CD44 receptors are
significantly overexpressed receptors on several tumour
cells compared to normal cells. Therefore, introducing folic
acid to chitosan,[223] polyspermine,[141] chondroitin sulfate-
PEI,[222] and dextran[148,163] led to enhanced immunisation in
hepatocellular, lung, and ovarian cancer, respectively. Biopo-
lymer scaffolds, such as endogenous polysaccharides, HA, and
chondroitin sulfate, specifically bind to CD44 receptors.
2.5. Designing Carriers that Enable Endosomal Escape
A major challenge drug and gene delivery systems are
facing is their entrapment in endosomes. Endosomes are
organelles responsible for intracellular sorting and contain
numerous enzymes. If the genetic material remains entrapped
in the endosome, it is degraded by lysosomal proteases, which
ultimately results in low transfection efficacy. In order to
escape endolysosomal degradation, several mechanisms are
involved in this process, such as pore formation in the
endosomal membrane, the pH buffering effect, and the fusion
into the lipid bilayer.[233]
Throughout the maturation of the endosomes, the pH
decreases from physiological pH 7.4 to pH& 6.5 in the early
endosome, pH& 6.0 in the late endosome and pH& 5.0 in the
lysosome due to the activity of membrane-bound ATPase
pumps (proton pumps), which pump protons across the
endosome and lysosome membrane into the vesicle interior
through ATP hydrolysis.[234] The presence of cationic poly-
mers, such as PEI,[91, 142,144, 147, 152,235] polyamidoamine,[151] suc-
cinyl tetraethylene pentamine,[164] spermine,[89,139–141, 161, 162,236]
and imidazole-containing molecules, such as histidine,[83, 90]
can all lead to endosomal rupture via the “proton-sponge”
effect. This effect is associated to the large buffering ability of
these molecules due to proton binding, which leads to more
protons being pumped. Consequently, this results in accumu-
lation of chloride ions and water, osmotic swelling, and
ultimately rupture of endosomes. Even though this mecha-
nism has been extensively used to explain the endosomal
rupture, it has been heavily debated.[234] Nevertheless, mole-
cules with high buffering capacity have been shown to play an
important role in enabling endosomal escape and have been
employed to enable the release of genetic material. For
example, Cheng et al.[153,154] have designed dextran nano-
carriers containing histidine-rich peptides as a promising
material for safe and efficient gene therapy. In their study,
dextran was grafted with arginine–histidine peptides (RxHy),
and low cytotoxicity as well as high gene expression were
achieved by using low molecular weight dextran carriers with
a high degree of substitution. The presence and ratio of
histidine was important both for the DNA condensation and
the control of endosomal escape, while arginine residues were
primarily used for DNA condensation and enhanced cell
uptake. This and other studies[64, 83, 90,139] demonstrated the
advantage of imidazole substituents and indicated a possible
route to designing efficient DNA vaccine carriers.
In addition to functional groups with high buffering
capacity, it was also shown that endosomal escape can be
enhanced in the presence of molecules able to penetrate
lysosomes (lysosomotropic agents), such as chloro-
quine,[237, 238] cationic lipids,[239] and membrane-disrupting
peptides.[159, 240] The latter are particularly interesting as they
are mainly derived from viral and bacterial vectors, which
developed efficient strategies to escape endosomes.[233] For
example, membrane-disrupting peptides, such as haemagglu-
tinin subunit 2 (HA2),[240] a fusogenic peptide from influenza
virus, and LLO, a cholesterol-dependent toxin produced by
Listeria monocytogenes,[241] have been used to modify pDNA
delivery systems and enhance delivery into the cytosol of the
target cells. Although their mode of action is different, they
both result in endosomal escape. While HA2 undergoes
conformational change during acidification, which enables
fusion trough the endosomal membrane, LLO is active at low
pH but is degraded in the cytosol and enables endosomal
escape through the formation of pores in lipid bilayers.[80]
2.6. Improved pDNA Release and Delivery to the Nucleus
Dissociation of the pDNA from the nanocarrier is one of
the most important steps in achieving higher transfection
efficacies. Efficient release can be achieved either by masking
the strong electrostatic interaction of pDNA and the carrier
or by introduction of a stimuli-responsive degradation system.
Masking of the positive charge is probably the simpler, but
less controllable route and can be achieved by introducing
a second polymer to the nanocarrier. For example, it was
reported that incorporating polyanionic polymers, such as
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alginate[200,201, 242] and poly(g-glutamic acid),[108,109] or a nega-
tively charged protein like a-casein,[243] into chitosan nano-
structures can reduce the strength of the interaction between
DNA and the particles, facilitating release and increasing
transfection. However, it should be noted that this could also
lead to a loss of DNA as it is transported to the cell of interest.
Studies have also demonstrated that the net positive
charge can be decreased by grafting hydrophobic molecules
such as l-phenylalanine[102] or by addition of flexible bulky
groups, such as pullulan.[64] Additionally, Xu and co-workers
integrated a dendritic lipopeptide, a charge-reversible poly-
mer, and an APC-targeting material into a DNA vaccine
delivery system through layer-by-layer assembly.[51] They used
poly(allylamine hydrochloride)-citraconic anhydride, a com-
monly used charge-reversible polymer, which can be hydro-
lysed in mild acidic environments in endosomes, resulting in
the destabilisation of the carriers and release of pDNA.
Compared to the traditionally used cationic polymer, PEI25k,
the carrier system based on the charge-reversible polymer
resulted in lower toxicity and eight-fold higher transfection
efficiency.
However, a more controllable route to pDNA release is
the use of stimuli-responsive linkers. In DNA vaccine systems,
stimuli-responsive disintegration of the carrier is mainly
achieved by incorporation of disulfide bonds and pH-sensitive
bonds.
The disulfide bond (-S@S-) can be cleaved into thiols
(-SH) in the presence of intercellular glutathione.[244] The
concentration of glutathione is around 100–1000 times higher
in several intracellular compartments compared to the
extracellular environment (2–10 mm compared to 2–20 mm),
which contributes to the efficient cleavage of disulfide
modified polymers.[245] This strategy was employed to facili-
tate unpacking of pDNA from polymer carriers such as
dextran,[148, 163] HA,[69] polyarginine,[90] and LLO,[79,80] which
were modified with positively charged groups via disulfide
bonds.
In addition to disulfide bonds, acid-degradable ketal
esters,[89] diacrylate cross-linkers,[141] and bis-amide bonds[139]
were used to improve the release of DNA from polyspermine
gene delivery systems in acidic environment.
Furthermore, Liu and co-workers have reported the
dissociation of pDNA from dextran–quantum dots[246] ena-
bled by cleaving the C=N bond in Schiff bases in acidic
conditions (pH< 6.5).[247]
In another study, Wang and co-workers have designed
a PDA–PEI nanovector bound to PEG–phenylboronic acid
via a pH-responsive boronate-ester bond.[185] They have
shown that the complex remained stable at physiological pH
but could be cleaved after internalisation in endosomes.
Additionally, near-infrared (NIR)-light irradiation and good
photothermal conversion of the carrier system has resulted in
quick endosomal release. In response to the acidic pH within
cancer cells and the NIR light irradiation, the nanovector was
able to overcome multiple barriers and result in efficient gene
delivery.
Once released, pDNA needs to enter the nucleus to be
transcribed for successful DNA vaccination. To aid the
nuclear transport of the genetic material, carriers can be
additionally modified with a nuclear localisation signal
(NLS). NLS is a short peptide with high content of positively
charged lysines or arginines, derived from eukaryotic nuclear
proteins and viral proteins, which can efficiently mediate
intranuclear transport.[248] Guan et al. introduced NLS
derived from simian virus 40 (SV40) large T antigen to
a cationic HSA–DNA system, significantly increasing its
gene expression efficacy in vitro and in vivo.[190]
Similarly, protamine, an arginine-rich protein commonly
used for DNA condensation and membrane translocation, has
been shown to aid the nucleus uptake when attached to
biodegradable anionic polymers such as chondroitin sul-
fate[135] or hydrophobic moieties such as cholesterol.[83] This
increase in nuclear transport is attributed to the presence of
NLS-like regions consisting of four to six arginine repeats.
2.7. DNA Vaccine Delivery Materials with Immunostimulatory
Effects
As outlined in Section 1.1., immunostimulants, such as
IFN-g, IL-2, or IL-4, play an important role during an immune
response, i.a. through promoting T cell differentiation. This is
the reason why vaccine formulations often contain adjuvants.
Adjuvants are organic or inorganic vaccine additives, for
example, aluminum salts in hepatitis vaccines or monophos-
phoryl lipids in shingles vaccines, and are employed to trigger
a stronger immune response, for example through stimulating
the secretion of immunostimulants.[249]
Adjuvants have also been employed to boost the immu-
nogenicity of DNA vaccines. For example, Jiang et al.
reported that modifying chitosan NPs with methacrylate-
based polymers resulted not only in a significant stabilisation
of DNA, but also led to higher antibody levels and IFN-g
secretion compared to the administration of naked DNA.[209]
Further to these findings, Yue and co-workers reported
that the introduction of CpG motifs to chitosan-NP-carriers
increased T-cell proliferation, the production and release of
IFN-g, IL-2, as well as IL-4.[250] The CpG motif is a well-
studied adjuvant in gene delivery and consists of a short,
synthetic single-stranded DNA sequence, which contains
mostly cytosine and guanine building blocks. In nature, the
unmethylated CpG motif can be found in bacterial genomes,
but it is very rare in the vertebrate genome. Thus, when
brought into the organism of a vertebrate, the foreign CpG
DNA is recognised as an invading species, which results in
a strong immune response. In a nutshell, CpG represents
a pathogen-associated molecular pattern (PAMP), which is
recognised by a specific pattern recognition system in TLR-9
of APCs.[251]
Interestingly, not only the addition of adjuvants but also
the size of the carrier complex plays a role in provoking an
immune response. This phenomenon was observed in various
inorganic and biopolymeric delivery systems. However, no
universal, linear size–immune-response relationship was
derived, indicating that other factors, including shape, chem-
ical composition, surface modification, and charge of the
carrier, contribute, too.[252] While Yue and co-workers found
that smaller CpG-modified chitosan NPs triggered a stronger
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immune response than larger particles,[250] Kim et al. explored
the potential of monodispersed polypyrrole NPs and discov-
ered that medium-sized NPs (60 nm in diameter) caused
a stronger immune response than their smaller and larger
counterparts.[253] These studies point towards the need for
a rational design approach that aims to address different
factors related to stability, solubility, transport, and immune
system response of DNA vaccines.
3. Conclusion and Future Directions
DNA vaccines have been developed as a suitable alter-
native to conventional vaccines. Despite not being approved
for human use yet, numerous DNA vaccine formulations have
been proposed and used in clinical trials to tackle, i.a., viral
and bacterial infections, parasites, as well as cancers. There
are several advantages of DNA vaccines that should prompt
more studies in the field. DNA vaccines are cheaper to make
and easier to formulate than conventional vaccines. They are
based on the expression of antigens, which can be presented
to immune cells, making them versatile and adaptable to
a range of diseases. However, pressing challenges remain,
including the difficulty of administering genetic material
precisely and safely as well as the low immunogenicity of the
first formulations. Some of these obstacles have been over-
come by using DNA nanocarriers, based on polymers, lipids,
and inorganic materials. Biopolymer-based nanomaterials are
particularly promising carrier candidates due to their intrinsic
biocompatibility, biodegradability, sustainable availability,
and manifold possibilities to modulate their physicochemical
and biological properties by adjusting the size, chemical
composition, or surface functionalisation. These materials can
be further modified to improve their solubility and stability,
ability to immobilise DNA, cellular uptake, intracellular
release, as well as immunogenicity.
The promising initial advances of biopolymer-based DNA
vaccines, particularly for the treatment of cancers, are
reassuring, but the major challenge of the field, the insuffi-
cient immune response in humans through administered
DNA, abides. Hence, the field will need to focus on trans-
lating the promising results of preclinical studies, commonly
conducted in small mammals and non-human primates, to
efficient human therapies. This is often very difficult due to
the significantly different structure of the immune system in
humans and animals. Furthermore, we expect that particu-
larly for complex diseases, like cancer, clinicians will embrace
an approach based on the combination of therapies, such as
checkpoint inhibition, cell therapy, and DNA vaccines to
address the issue of low immunogenicity in the future.
Recently, combinational approaches have also been
employed in dealing with coronavirus infections, wherein
antivirals and anti-inflammatory agents are being used to
counter viral replication and respiratory distress, respectively.
Administration of vaccines alongside these conventional
therapies will effectually counter the virus that enters the
body.
A development we will need to see in the next few years is
a more efficient identification of biomarkers, which will
enable development of diagnostic strategies and provide us
with the information on patients most likely to benefit from
use of the DNA vaccine approaches. A more nuanced and
holistic understanding of immunological markers and their
correlation to vaccine efficacy will inform us about polymer
design and its subsequent delivery strategy.
Finally, scale up of vaccine-based delivery systems with
focus on reproducibility and stability is another crucial aspect
to consider both during the carrier material design and
implementation in the clinic. We believe that in this context,
biopolymers will emerge as sustainable and scalable material
of choice for the formulation of DNA and mRNA vaccines, as
their monomers are readily available and their production is
cost-effective. The next few years will see more research in
the field of biopolymer-based DNA vaccines to increase their
in vivo efficacy and ultimately enable their application in the
clinic.
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